Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CB-TGFBR2/NR3C1 KO NK cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on CB-TGFBR2/NR3C1 KO NK cells, putative cord blood-derived allogeneic natural killer (NK) cells engineered to knockout TGFBR2 and NR3C1 (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CB-TGFBR2/NR3C1 KO NK cells | CB-NK-TGF-betaR2-/NR3C1- cells | Limited information is currently available on CB-TGFBR2/NR3C1 KO NK cells, putative cord blood-derived allogeneic natural killer (NK) cells engineered to knockout TGFBR2 and NR3C1 (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04991870 | Phase I | CB-TGFBR2/NR3C1 KO NK cells | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | Recruiting | USA | 0 |